Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Those interested in additional support for the fat loss phase can also review the supplements to take with GLP-1 guide and the best peptide stack for weight loss resource, which covers how different compounds can be combined with GLP-1 medications for enhanced outcomes
Activities that engage the core and promote general movement are beneficial
Safety Profile The most common adverse events documented across retatrutide results data were gastrointestinal in nature, with incidence increasing at higher doses: Nausea: 6-31% (dose-dependent), primarily during escalation periods Diarrhea: 6-25%, generally mild to moderate Vomiting: 0-16%, occurring mainly in the first weeks of each dose increase Decreased appetite: 3-19%, which contributed to the weight reduction effect Constipation: 3-12%, consistent with GLP-1 receptor-mediated gastric slowing Serious adverse events were rare across all cohorts
Clinical evidences on the DPP-4 inhibitor sitagliptin suggests it is associated with a decreased risk of prostate cancer [106, 110], and long-term administration of this agent may have potential benefits for breast cancer [96]
The content and findings reported and illustrated are the sole deduction, view and responsibility of the researchers and do not reflect the official position and sentiments of the funders
